(Q81543334)

PubMed publication ID

18586923

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586923%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Characteristics and outcome of pediatric patients enrolled in phase I oncology trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

main subject

phase I clinical trial

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

author name string

Aerang Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Elizabeth Fox

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Katherine Warren

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Susan M Blaney

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Stacey L Berg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Peter C Adamson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Madeleine Libucha

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Elena Byrley

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

Brigitte C Widemann

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

publication date

1 June 2008

1 reference

PubMed publication ID

18586923

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18586923%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

page(s)

679-689

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial

13 May 2020

cites work

1 reference

12 December 2020

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

1 reference

12 December 2020

Phase I therapy trials in children with cancer

1 reference

12 December 2020

Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.

1 reference

12 December 2020

Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial

1 reference

12 December 2020

Bone marrow aplasia due to radiation accidents: pathophysiology, assessment and treatment

1 reference

12 December 2020

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

1 reference

12 December 2020

Conduct of phase I trials in children with cancer

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.

1 reference

12 December 2020

Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers

1 reference

12 December 2020

The Challenge of Developing New Therapies for Childhood Cancers

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.

1 reference

12 December 2020

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors

1 reference

12 December 2020

Pediatric phase I trials in oncology: an analysis of study conduct efficiency

1 reference

12 December 2020

Patients who are receiving concomitant medications should not systematically be excluded from phase I studies

1 reference

12 December 2020

Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer

1 reference

12 December 2020

A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.

1 reference

12 December 2020

Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.

1 reference

12 December 2020

Clinical trial design for target-based therapy

1 reference

12 December 2020

New approaches to drug development in pediatric oncology

1 reference

12 December 2020

Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials

1 reference

12 December 2020

Developing new agents for the treatment of childhood cancer.

1 reference

12 December 2020

10.1634/THEONCOLOGIST.2008-0046

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6953426&resulttype=core&format=json

13 May 2020

PubMed publication ID

18586923

1 reference